
Iterum Therapeutics PLC
NASDAQ:ITRM

Fundamental Analysis


Revenue & Expenses Breakdown
Iterum Therapeutics PLC
Balance Sheet Decomposition
Iterum Therapeutics PLC
Current Assets | 13.5m |
Cash & Short-Term Investments | 12.7m |
Receivables | 19k |
Other Current Assets | 842k |
Non-Current Assets | 19.5m |
PP&E | 37k |
Intangibles | 19.4m |
Other Non-Current Assets | 21k |
Free Cash Flow Analysis
Iterum Therapeutics PLC
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Iterum Therapeutics PLC
Revenue
|
0
USD
|
Cost of Revenue
|
-596k
USD
|
Gross Profit
|
-596k
USD
|
Operating Expenses
|
-15.6m
USD
|
Operating Income
|
-16.2m
USD
|
Other Expenses
|
-6.3m
USD
|
Net Income
|
-22.6m
USD
|
ITRM Profitability Score
Profitability Due Diligence
Iterum Therapeutics PLC's profitability score is 49/100. The higher the profitability score, the more profitable the company is.

Score
Iterum Therapeutics PLC's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
ITRM Solvency Score
Solvency Due Diligence
Iterum Therapeutics PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Score
Iterum Therapeutics PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ITRM Price Targets Summary
Iterum Therapeutics PLC
According to Wall Street analysts, the average 1-year price target for
ITRM
is 5.1 USD
with a low forecast of 5.05 USD and a high forecast of 5.25 USD.
Dividends
Current shareholder yield for ITRM is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?